Document is current
Any future updates will be listed below
-
Authors
Tiu, Bruce C https://orcid.org/0000-0002-2815-5579
Zubiri, Leyre https://orcid.org/0000-0003-4226-7443
Iheke, James
Pahalyants, Vartan https://orcid.org/0000-0003-4671-620X
Theodosakis, Nicholas
Ugwu-Dike, Pearl
Seo, Jayhyun
Tang, Kimberly
Sise, Meghan E
Sullivan, Ryan https://orcid.org/0000-0001-5344-6645
Naidoo, Jarushka https://orcid.org/0000-0002-3470-8686
Mooradian, Meghan J https://orcid.org/0000-0002-8289-8015
Semenov, Yevgeniy R
Reynolds, Kerry L https://orcid.org/0000-0002-7793-654X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04438382 at ClinicalTrials.govnct04438382 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
https://doi.org/10.1136/jitc-2021-002435
Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
https://doi.org/10.1136/jitc-2020-002252
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-001884
Corticosteroid-resistant immune-related adverse events: a systematic review
https://doi.org/10.1136/jitc-2023-007409
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
https://doi.org/10.1136/jitc-2020-001731
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
https://doi.org/10.1136/jitc-2022-004670
nct04438382 at ClinicalTrials.govDocuments that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
https://doi.org/10.1136/jitc-2021-002435
Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
https://doi.org/10.1136/jitc-2020-002252
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-001884
Corticosteroid-resistant immune-related adverse events: a systematic review
https://doi.org/10.1136/jitc-2023-007409
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
https://doi.org/10.1136/jitc-2020-001731
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
https://doi.org/10.1136/jitc-2022-004670
Documents that mention this clinical trial
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
https://doi.org/10.1136/jitc-2021-002435
Acknowledging and addressing real-world challenges to treating immune-related adverse events
https://doi.org/10.1136/jitc-2024-009540
Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis
https://doi.org/10.1136/jitc-2020-002252
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade
https://doi.org/10.1136/jitc-2020-001884
Corticosteroid-resistant immune-related adverse events: a systematic review
https://doi.org/10.1136/jitc-2023-007409
Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes
https://doi.org/10.1136/jitc-2020-001731
Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study
https://doi.org/10.1136/jitc-2022-004670
-
Funding
Funding for this research was provided by:
Pugh Scholar Fund
Spanish Society of Medical Oncology
- License Information
